CD285 TLR5 (Toll-like receptor 5)
Molecule TypeAntigen ExpressionMolecular Weight
Min / Max
Non-lineage Restricted Molecule
Type 1 glycoprotein
Leukocyte
Prostate
Liver
Ovary
Lung
Monocyte
Epithelium
Peripheral blood
Testis
120 / 120

Expression

CD285 is expressed on leukocytes and  mRNA.  High expression is in ovary, mucosal epithelium and in peripheral blood leukocytes especially in monocytes and moderate expression in CD11c+ immature dendritic cells.  Expression is also detected in prostate, testis, liver, breast milk and lung.



Structure
MOLECULAR FAMILY NAME: Belongs to the Toll-like receptor family.

CD285 is a single-pass type-1 838 aa glycoprotein.  It contains a 20 aa signal sequence, a 619 aa extracellular domain containing 15 leucine-rich (LRR) repeats capped at each end by N- and C-terminal motifs and has 7 potential N-glycosylation sites, a 21 aa transmembrane domain and an 198 aa intracellular cytoplasmic domain contains an 147 aa Toll/IL-1R domain which interacts with the adaptor molecule myeloid differentiation primary response gene MyD88.  The LRRs form a "horseshoe" shaped structure which is the ligand binding domain.  Approximately of the population which carries a CD290 poymorphism with a stop codon at position 392 (TLR5392STOP) leads to loss of the transmembrane and cytoplasmic domains.

MOLECULAR MASS

POST-TRANSCRIPTIONAL MODIFICATION: No information.

POST-TRANSLATIONAL MODIFICATION

CD285 has 7 potential glycosylation sites.

Ligands
LIGANDS AND MOLECULE ASSOCIATED WITH CD285

CD285 binds flagellin.

Function
CD285 plays a fundamental role in pathogen recognition and activation of innate immunity.  TLRs are highly conserved from Drosophilia to humans and share structural and functional similarities.  They recognize pathogen-associated molecular patters (PAMPs) that are expressed on infectious agents, and mediate the production of cytokines necessary for the development of effective immunity.  The various TLRs exhibit different patterns of expression.  Release of pro-inflammatory cytokines and immune cell activation occurs via the MyD88-dependent signaling pathway.  The activation of CD285 mobilizes the nuclear factor NF-κB and stimulates TNF-α production.  Acting via MyD88 and TRAF6, CD285 leads to NF-κB activation, stimulates TNF-α production,  cytokine secretion and inflammatory responses. 

BIOCHEMICAL ACTIVITY: No information.

DISEASE RELEVANCE AND FUNCTION OF CD285 IN INTACT ANIMAL

CD285 is expressed in myelomonocytic cells and recognizes bacterial flagellin, a principal component of bacterial flagella and a virulence factor.  Individuals with a stop codon polymorphism are prevented to mediate flagellin activated signaling and is associated with susceptibility to lung infections by bacterial pathogens such as Legionella pneumophila and Pseudomonas aeruginosa.  Flagellin/CD285 signaling is implicated in the progression of inflammatory bowel conditions such as colitis, inflammatory bowel disease and Crohn's disease.  Some bacterial pathogens, including Helicobacter pylori and Campylobacter jejuni, produce flagellin with specific changes to the CD285 binding site and are thus able to evade detection via CD285.

Comments
MOLECULAR INTERACTIONS-
PROTEINS AND DNA ELEMENTS WHICH REGULATE TRANSCRIPTION OF CD285: No information.

SUBSTRATES: No information.

ENZYMES WHICH MODIFY CD285: No information.

Database accession numbers
AnimalPIRSWISSPROTEMGBL/GENBANK
 
HumanEntrezgene7100O60602
Antibodies

Revised June 25, 2008


Contact us: Webmaster |  509-335-9515 | Accessibility | Copyright | Policies
College of Veterinary Medicine Washington State University, Pullman, WA, 99164-7010 USA
Copyright 1995-2003 Washington State University